NAMSA® Launches “Uniquely IVD” Development Services to Expedite In Vitro Diagnostic Technology Commercialization Efforts for Global Manufacturers
Summary
Due to the increased demand by patients and healthcare providers for more rapid diagnoses and treatment plans, the need for novel and highly-accessible IVD products will only intensify.Unlike other CROs, our team of IVD experts are solely focused on providing proven solutions for the unique challenges and needs of In Vitro Diagnostic technologies.This not only allows manufacturers to achieve clinical endpoints more quickly, but also helps them make more informed decisions that fast-track global delivery of life-changing IVD technologies,” concluded Ms. Schaaf.Driven by our regulatory expertise, NAMSA’s MRO® Approach plays an important role in translational research, applying a unique combination of disciplines – consulting, regulatory, preclinical, toxicology, microbiology, chemistry, clinical and quality – to move clients’ products through the development process, and continue to provide support through commercialization to post-market requirements, anywhere in the world.NAMSA operates 13 offices throughout North America, Europe, the Middle East and Asia, and employs 1,000 highly-experienced laboratory, clinical research and regulatory consulting Associates.